| 证券代码 | IDXG.O |
| 证券名称 | Interpace Biosciences Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 1998-05-20 |
| 首发价格(元) | 16 USD |
| 首发数量(股) | 2800000 |
| 首发募资额(元) | 44,800,000.00 USD |
| 首发主承销商 | Hambrecht & Quist LLC,Morgan Stanley & Co. Incorporated,William |
| 货币单位 | USD |
| 公司名称 | Interpace Biosciences, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | Morris Corporate Center 1, Building A, 300 Interpace Parkway, Parsippany, New jersey, USA |
| 成立日期 | 1998 |
| 董事会主席 | Robert Gorman |
| 公司属地 | United States 美国 |
| 公司网址 | www.interpacediagnostics.com |
| 电话 | +1 (844) 405-9655 |
| 传真 | - |
| 公司简介 | Interpace Biosciences, Inc. is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests, related first line assays and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts, biliary strictures and solid masses; ThyGenX (now ThyGeNEXT), for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay for indeterminate thyroid nodules that includes numerous additional molecular markers, gene mutations, and RNA fusions; ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. |